课题基金 / 基金详情

Alzheimer's Clinical Trials Consortium (ACTC)

Alzheimer's Clinical Trials Consortium (ACTC)
阿尔茨海默病临床试验联盟 (ACTC)
批准号:
10435786
负责人:
Paul S. Aisen
金额:
$23.05万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-12-02 至 2023-06-30
关键词:

项目摘要

项目成果

Paul S. Aisen的其他基金

相关文献

中文摘要
翻译
有了这一补充,我们请求支持扩大NIH包括试用就绪 队列-唐氏综合症(TRC-DS)项目,作为R61阶段(队列)的一部分 寻求招募120名患有DS的参与者,在该人群中进行抗淀粉样蛋白治疗的R33期安慰剂对照临床试验之前。具体的 TRC-DS项目的目标包括建立一个准备好的队列,既能为 临床试验的设计以及提供感兴趣和符合条件的参与者 收集了丰富的参与者水平的表型数据。热罗姆·勒琼研究所 是世界上领先的DS患者临床护理中心,包括 患有DS相关AD的老年人。将此站点添加到ACTC-DS网络以 参与TRC-DS项目将进一步推动 与一支优秀的研究团队进行项目合作并建立强有力的合作关系。
英文摘要
With this supplement, we request support to expand the NIH INCLUDE Trial-Ready Cohort-Down Syndrome (TRC-DS) project, which as part of the R61 phase (cohort) seeks to enroll 120 participants with DS, in advance of the R33 phase placebocontrolled clinical trial of an anti-amyloid therapeutic in this population. The specific aims of the TRC-DS project include building a readiness cohort that will both inform the design of a clinical trial as well as provide interested and eligible participants while collecting a rich set of participant-level phenotypic data. The Institute Jérôme Lejeune is a preeminent center in the world for clinical care of individuals with DS, including older adults with DS-related AD. Adding this site to the ACTC-DS network for participation in the TRC-DS project will further advance the impact and diversity of the project and establish a strong collaboration with an outstanding research team.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
  • 批准号:
    10554282
  • 项目类别:
  • 资助金额:
    $694.16万
  • 财政年份:
    2019
  • 负责人:
    Paul S. Aisen
  • 依托单位:
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
  • 批准号:
    10358480
  • 项目类别:
  • 资助金额:
    $694.33万
  • 财政年份:
    2019
  • 负责人:
    Paul S. Aisen
  • 依托单位:
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
  • 批准号:
    9930020
  • 项目类别:
  • 资助金额:
    $694.49万
  • 财政年份:
    2019
  • 负责人:
    Paul S. Aisen
  • 依托单位:
Combination anti-amyloid therapy for preclinical Alzheimer's disease